Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Stop Yakkasa-Based Business Immediately: FPMAJ President Morita
February 4, 2008
- Korosho Considers Joint Clinical Trial Consultation Services with the US and EU
February 4, 2008
- Preminent Most Heavily Promoted in December: Rep Track Survey
February 4, 2008
- Insurance Policies to Be Required for Clinical Research
February 4, 2008
- BUSINESS NEWS IN BRIEF
February 4, 2008
- Council Moving to Build Up Regional Clinical Trial Systems
February 4, 2008
- NEW PRODUCTS
February 4, 2008
- Public Opinions Invited on Draft Guidance on MD Studies
February 4, 2008
- GENERICS NEWS IN BRIEF
February 4, 2008
- Article 35 of the Amended Patent Law Should Be Properly Applied: Dr Akimoto
February 4, 2008
- How Can We Maximize the Value of Our Brand？
February 4, 2008
- R&D NEWS IN BRIEF
February 4, 2008
- Outline of FY2008 Revision of Medical Fees Approved by Chuikyo
February 4, 2008
- Cardiac Reagent NT-proBNP: RDKK
February 4, 2008
- Re-Pricing for Market Expansion Discourages Investment: PhRMA
February 4, 2008
- SELF-MEDICATION NEWS IN BRIEF
February 4, 2008
- 13 APIs Receive Approval Including Nexavar and Champix
February 4, 2008
- Risk of Death Decreases with Increases in Total Cholesterol Levels: Prof Hamazaki
February 4, 2008
- 42 New Technologies, 24 "Advanced Medical Technologies" Recommended for Insurance Coverage
February 4, 2008
- Precautions on "Impaired Performance" Necessary for Antihistaminics: sanofi-aventis
February 4, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…